ScinoPharm and Lee's Pharma jointly develop drugs for the Chinese market
Taiwan API specialist ScinoPharm Taiwan (TWSE: 1789) and Lee's Pharmaceutical Holdings (950: HK) have entered into two collaborations whereby they will jointly develop and produce fondaparinux, an anti-thrombotic agent and travoprost and bimatoprost, two prostaglandin derivative drugs for treating glaucoma.
Capitalizing on the strengths and expertise of the two companies, the products are expected to offer competitive advantages on entering into the Chinese high-end generic drug market, the drugmakers say.
These drugs have extremely high technical entry barriers in process development and manufacturing. This collaboration takes the advantages of the two sides, ie, the R&D strengths of ScinoPharm in the development and manufacturing of highly potent APIs, coupled with Lee's wealth of experience in developing and manufacturing ophthalmic products plus its outstanding marketing channels in China.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze